背景:拔牙手术通常会导致骨吸收,这可能会对牙槽骨的尺寸产生不利影响。研究表明,在这种情况下,使用骨移植替代品的插座保存技术可以有效地减少早期骨丢失。α-硫酸钙半水合物(α-CSH)作为一种潜在的骨移植材料,由于其良好的性能而受到了广泛的关注。包括骨传导性,血管生成潜力,和生物相容性。考虑到这些事实,我们开发了应用α-CSH解决拔牙后牙槽骨丢失的初步方案。
目的:这项研究的总体目标是评估α-CSH作为拔牙后保留牙槽的骨诱导移植材料的可行性和初始有效性。
方法:这项初步临床试验将涉及30个来自18-35岁个体的新鲜拔牙槽。参与者将分为2组:一组将在拔牙后接受α-CSH移植材料以保存牙槽,而另一组不会接受任何移植材料。在整个研究过程中,将密切监测参与者的安全措施,其中包括临床检查,射线成像,和血液测试。射线照相成像将被广泛地用于辅助骨形成的进展。
结果:该研究于2022年8月开始注册,并计划于2023年底结束后评估和分析。这项研究的结果预计将在2024年底公布。
结论:这项临床研究代表了在人类中评估α-CSH在牙槽骨再生中的可行性和功效的初步研究。我们假设包含α-CSH可以大大加快新鲜插座内骨形成的过程,导致骨高度的迅速恢复,而没有与收获自体骨移植物相关的缺点。
背景:印度尼西亚注册中心INA-D02FAHP;https://tinyurl.com/2jnf6n3s。
■DERR1-10.2196/49922。
BACKGROUND: Tooth extraction procedures often lead to bone resorption, which can have adverse effects on the dimensions of the alveolar ridge. Research has shown that socket preservation techniques using bone graft substitutes can effectively minimize early bone loss in such cases. α-calcium sulfate hemihydrate (α-CSH) has garnered significant attention as a potential bone graft material due to its favorable properties, including osteoconductivity, angiogenic potential, and biocompatibility. Considering these facts, we developed a preliminary protocol for applying α-CSH in addressing alveolar bone loss following tooth extraction.
OBJECTIVE: This research\'s general objective is to evaluate the feasibility and initial effectiveness of α-CSH as bone-inducing graft material for socket preservation after tooth extraction.
METHODS: This preliminary clinical trial will involve 30 fresh extraction sockets from individuals aged 18-35 years. The participants will be divided into 2 groups: one group will receive α-CSH graft material after tooth extraction for socket preservation, while the other group will not receive any graft material. Throughout the study, the participants will be closely monitored for safety measures, which will include clinical examinations, radiographic imaging, and blood tests. Radiographic imaging will be used extensively to assist the progress of bone formation.
RESULTS: The study commenced enrollment in August 2022 and is scheduled to conclude post assessments and analyses by the end of 2023. The results of the study are anticipated to be accessible in late 2024.
CONCLUSIONS: This clinical study represents the initial investigation in humans to assess the feasibility and efficacy of α-CSH in alveolar bone regeneration. We hypothesize that the inclusion of α-CSH can greatly expedite the process of bone formation within fresh sockets, resulting in a swift restoration of bone height without the disadvantages associated with harvesting autogenous bone graft.
BACKGROUND: Indonesia Registry Center INA-D02FAHP; https://tinyurl.com/2jnf6n3s.
UNASSIGNED: DERR1-10.2196/49922.